Engineered AAV Vectors for Targeted Gene Delivery to Specific Body Parts

This patent describes specially designed adeno-associated virus (AAV) vectors that can deliver new genetic material to specific tissues in the body, such as the brain, heart, or retina, to treat diseases.

What it covers

This patent relates to engineered adeno-associated (AAV) vectors. These vectors are modified viruses used to carry new genes into cells. The engineering allows these AAV vectors to specifically deliver genetic material, called transgenes, to particular parts of the body. For example, the patent mentions targeting the central nervous system (CNS), peripheral nervous system (PNS), inner ear, heart, or retina. This means the vectors are designed to express a desired gene primarily in cells within these specific organs or tissues. The patent also describes methods for finding new engineered AAV vectors that can deliver genes to desired cell types.

What it doesn't cover

• —Does not cover gene delivery methods that use viral vectors other than adeno-associated viruses (AAV).
• —Does not cover AAV vectors that are not specifically engineered for targeted transgene expression.
• —Does not cover AAV vectors used for purposes other than delivering and expressing a transgene, such as direct gene editing without expression.
• —Does not cover delivery of genetic material to tissues or organs not mentioned in the abstract, unless they fall under the broad categories of CNS or PNS.
• —Does not cover general, non-engineered AAV vectors that lack specificity for particular cell types or tissues.

The clever bit

The novelty lies in engineering AAV vectors to specifically target certain cell types and tissues, like the brain or retina, for transgene expression. This precise targeting improves the safety and effectiveness of gene therapy by ensuring the therapeutic gene reaches the right place and avoids unintended cells.

Why it matters

Targeted gene delivery is crucial for gene therapy, allowing treatments to reach only the affected cells while minimizing side effects elsewhere in the body. This approach can lead to more effective therapies for genetic diseases affecting specific organs like the eye or heart. The ability to precisely deliver genes opens doors for treating conditions that currently have limited options.

Real-world examples

• 1.Luxturna (voretigene neparvovec-rzyl) for inherited retinal disease
• 2.Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy
• 3.Gene therapies targeting specific neurological disorders
• 4.Experimental treatments for certain heart conditions
• 5.Research into therapies for hearing loss affecting the inner ear